Clinical trials: B-lymphocytes
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma
- Trial name
- NCT03712202
- Testing
- Bleomycin, Brentuximab Vedotin, Dacarbazine
- Where
- 17 sites in United States
- Volunteers
- 159 people
- Sponsor
- City of Hope Medical Center
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
- Trial name
- NCT03907488
- Testing
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography
- Where
- 728 sites in United States, Canada and 1 more
- Volunteers
- 994 people
- Sponsor
- National Cancer Institute (NCI)
Lymphocytes
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors.
- Trial name
- NCT06047977
- Testing
- Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
SCID, Omenn's Syndrome
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
- Conditions
- SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome
- Trial name
- NCT01652092
- Testing
- Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
This phase II trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte…
- Conditions
- Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
- Trial name
- NCT00107198
- Testing
- Conventional Surgery, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 170 sites in United States, Australia and 4 more
- Volunteers
- 188 people
- Sponsor
- Children's Oncology Group
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
- Trial name
- NCT06098430
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- St. Jude Children's Research Hospital
Microbiota, B-lymphocytes
INS, B Cells and Microbiota
Idiopathic nephrotic syndrome (NIS) is a clinical entity defined by the association of selective albuminuria, hypoalbuminemia, and nonspecific glomerular lesions (lesions minimal glomerular (LGM) or segmental and focal hyalinosis…
- Conditions
- Microbiota, B-lymphocytes, Glomerulosclerosis, T-lymphocytes
- Trial name
- NCT04924712
- Testing
- Measurement of blood immune populations and microbiota distribution.
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma, Acute Myeloid Leukemia
National Longitudinal Cohort of Hematological Diseases
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
- Trial name
- NICHE (NCT04645199)
- Where
- China
- Volunteers
- 2,300 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
S100B, Neutrophils/Lymphocytes Ratio
Protein S100B Versus Neutrophils/Lymphocytes Ratio in Early Prediction of Brain Injury
The study aimed to evaluate the role of Protein S100B versus the neutrophil-to-lymphocyte ratio (NLR) as an early predictor biomarker and the value of amplitude-integrated electroencephalography (aEEG) as an early predictor and…
- Conditions
- S100B, Neutrophils/Lymphocytes Ratio, Prediction, Brain Injury
- Trial name
- NCT07093723
- Testing
- S100B Protein, Neutrophils to Lymphocytes ratio
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Cytomegalovirus Viremia, Cytomegalovirus Pneumonia
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).
- Conditions
- Cytomegalovirus Viremia, Cytomegalovirus Pneumonia, T-Lymphocyte Immunodeficiency
- Trial name
- NCT07015801
- Testing
- CMV-VST
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Pancreatic Cancer, Adult, Perineural Invasion
Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
Pancreatic cancer has an incidence of 1,401,450 new cases diagnosed annually worldwide and is the third leading cause of cancer-related death in Spain.
- Conditions
- Pancreatic Cancer, Adult, Perineural Invasion, Neutrophil-to-Lymphocyte Ratio, CA 19.9
- Trial name
- NCT06747481
- Where
- Spain
- Volunteers
- 323 people
- Sponsor
- University of Las Palmas de Gran Canaria
Congenital Heart Disease, Tetralogy of Fallot
Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome
Tetralogy of Fallot (ToF) were cyanotic congenital heart disease with chronic hypoxia which increases the risk of exacerbated inflammatory response in ToF primary repair.
- Conditions
- Congenital Heart Disease, Tetralogy of Fallot, Neutrophil-lymphocyte Ratio, Absolute Lymphocyte Count
- Trial name
- NCT05976204
- Testing
- ToF primary repair
- Where
- Indonesia
- Volunteers
- 501 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Nephrotic Syndrome, Infections
The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
The goal of this observational study is to test whether the dynamic changes of CD4+T lymphocytes can predict infections in patients with primary nephrotic syndrome .
- Conditions
- Nephrotic Syndrome, Infections, Lymphocyte
- Trial name
- NCT05623033
- Testing
- The study is an observational study without intervention
- Where
- China
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Hemoglobins, Albumins
Association Between Preoperative HALP and Immediate Postoperative Outcomes
Multiple inflammation-based prognostic scores have been developed for the prediction of perioperative morbidity and mortality following pancreaticoduodenectomy (PD).
- Conditions
- Hemoglobins, Albumins, Platelets, Lymphocytes
- Trial name
- NCT05506748
- Testing
- pantients undergoing pancreaticoduodenectomy
- Where
- Nepal
- Volunteers
- 22 people
- Sponsor
- Chitwan Medical College
Posterior Reversible Encephalopathy Syndrome, Inflammatory Biomarkers
Inflammatory Biomarkers for the Diagnosis of oPRES
The purpose of this study is to explore the inflammatory biomarkers for the diagnosis of obstetric posterior reversible encephalopathy syndrome.
- Conditions
- Posterior Reversible Encephalopathy Syndrome, Inflammatory Biomarkers, Neutrophil-lymphocyte Ratio
- Trial name
- NCT05433870
- Testing
- Whether the PE or E patient combined with PRES
- Where
- China
- Volunteers
- 621 people
- Sponsor
- Dunjin Chen
Lymphocyte Disorder, Nephrotic Syndrome
Characteristics of Peripheral Blood Lymphocyte Subsets in Children With PNS
The etiology and precipitating factors of PNS remain unclear. Dysfunction of immunologic function is a classic theory of the pathogenesis of PNS.
- Trial name
- NCT05392244
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma.
- Conditions
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT01026220
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate
- Where
- 177 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Children's Oncology Group
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
This phase III trial is studying how well combination chemotherapy works when given before radiation therapy and/or additional chemotherapy in treating young patients with newly diagnosed Hodgkin's lymphoma.
- Conditions
- Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00302003
- Testing
- radiation therapy, doxorubicin hydrochloride, vincristine sulfate
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Children's Oncology Group
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
This phase II trial studies the side effects and efficacy of bortezomib with ifosfamide and vinorelbine in children and young adults with Hodgkin's lymphoma that was recurrent or did not respond to previous therapy.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Trial name
- NCT00381940
- Testing
- ifosfamide, bortezomib, vinorelbine tartrate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital